Aptamers Market Size valued at USD 2.3 Billion in 2022. The Aptamers market industry is projected to grow from USD 2.74 Billion in the year 2023 to USD 11.42 Billion by 2032, exhibiting a compound yearly growth rate (CAGR) of 19.50% during the forecast period (2023 - 2032). Increased research and development expenditure and regular advancement in technologies are the key market drivers enhancing the growth of market.
Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review
Market CAGR for aptamers is being driven by the rising investment in research and development and applications. The aptamers market has witnessed various investments for R&D by pharmaceutical companies, academic institutions, biotechnology firms, and government organizations in recent years, and it is expected to continue in the coming years. The rising requirement to explore and utilize the unique properties of aptamers for different applications is boosting investments in the research and development of aptamers.
The rising adoption of technological advancements enhances the growth rate of the aptamers market. high efficiency and low cost in binding the large molecules compared to antibodies, and the patent expiration of systematic evolution of ligands by proliferating enrichment technology. The benefits of aptamers, like high specificity, less immunogenicity, and ease of synthesis when compared to traditional therapeutics, the surging demand for targeted therapies, growing utilization of aptamers in the biosensors, diagnostic assays, and imaging techniques, and fast shift towards precision medicine fuel the growing rate of the aptamer market. The rising number of FDA approvals for aptamers, growing awareness within the market participants and supporting pipeline, fast adoption aptamers in the food and chemical industries, and surging demand from the public owing to its advantages, like, their high efficiency and minimum cost when compared to antibodies, thus boosting the market growth.
The antibodies have few limitations in targeting small molecules; on the other hand, aptamers perform better in targeting small molecules. They have the ability to bind to small molecules and dyes and can therefore be utilized in conventional diagnostic kits, expanding their use to point-of-care diagnostics. This will confirm a better market value and increase in acceptance of aptamers for addressing both diagnostic and therapeutic applications. Further, aptamers can also bind to large molecules, and 98% of the molecules are proteins, making it simpler to discover biomarkers and diagnostic kits. Thus, driving Aptamer's market revenue.
However, the lack of awareness among researchers, professionals, and end-users about the potential benefits and applications of aptamers is one of the key factors restraining the aptamers' growth of the market. The higher cost related to aptamer development, manufacture, and optimization, the challenging regulatory landscape for aptamers and the limited availability of commercially viable aptamers, and the competition from other established technologies like small molecules, antibodies, and peptides further hampers the growth of the market.
The Aptamers market segmentation, based on type, includes Nucleic Acid Aptamer and Peptide Aptamer. The nucleic acid aptamer segment dominated the market, accounting for the largest market revenue. Currently, many companies are investigating the mechanism of action of nucleic acid aptamers in order to treat various disorders, including age-related muscular degeneration. Further, the peptide aptamer segment is anticipated to experience significant growth throughout the forecast years due to the broad application base for therapeutic and diagnostic purposes.
Figure 1 Aptamers Market, by Type, 2022 & 2032 (USD Billion)
Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review
The Aptamers market segmentation, based on application, includes Diagnosis, Therapeutics, Research & Development, and Others. The research & development segment dominates the market, accounting for the largest market revenue because of the increasing demand for aptamers. Rising research activities in this field have boosted the aptamers demand in the research and development field. There are different strategic initiatives taken by the major market players, like partnerships, collaboration, and agreements for R&D of new aptamers-based therapeutic and diagnostics products. Further, the therapeutics segment is anticipated to experience the fastest growth due to the ability to fabricate antidotes rationally and is thought to be the better alternative than protein therapeutics in terms of synthetic accessibility, modification, and size by medical chemistry.
By region, the study gives the market insights into the North America, Europe, Asia-Pacific, and the Rest of the World. The North American Aptamers market area dominates the market owing to the prevalence of the chronic diseases, rising interest of research laboratories in the aptamer field, and strong healthcare infrastructure in this region. Further, the availability of key market players and fast adoption of precision medicine approaches in the North American region. The US is the largest contributor to the growth of the market in this region.
Further, the prime countries studied in the market report are the US, Canada, France, the UK, German, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil.
Figure 2 APTAMERS MARKET SHARE BY REGION 2022 (USD Billion)
Source The Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe's Aptamers market accounts for the second-largest market share due to the rising demand for aptamers therapies and the approval of new aptamer-based products, and the surging prevalence of the chronic diseases in this region. Further, the German Aptamers market held the largest market share, and the UK Aptamers market was the fastest growing market in European region.
The Asia-Pacific Aptamers Market is expected to grow at the rapid CAGR from 2023 to 2032. This is due to surging R&D investments in the biotechnology & pharmaceutical industries, a growing patient population base, rising healthcare expenditure, and growing focus on personalized medicine in this region. Moreover, China’s Aptamers market held the largest market share, and the Indian Aptamers market was the fastest-growing market in the Asia-Pacific region.
Aptamers Key Market Players & Competitive Insights
Leading market players are investing hugely in research and development in order to expand their product lines, which will help the Aptamers market grow even more. Market players are also undertaking a variety of strategic activities to spread their footprint, with important market developments inclusive of new product launches, higher investments, contractual agreements, mergers and acquisitions, and collaboration with other organizations. To spread and survive in a more competitive and rising market climate, the Aptamers industry must offer the cost-effective items.
Manufacturing locally to reduce the operational costs is one of the key business tactics used by the manufacturers in the Aptamers industry to benefit clients and increase the market sector. In recent years, the Aptamers industry has given some of the most significant advantages to the medicine. Major players in the Aptamers market, including SomaLogic Operating Co., Inc., Aptamer Group Inc, Aptagen LLC, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., Aptus Biotech SL, TriLink Biotechnologies, AstraZeneca, AM Biotechnologies, Aptadel Therapeutics, Ophthotech Corporation, and others, are trying to increase market demand by investing in the research and development operations.
Aptamer Group PLC offers Optimer binders for utilization in diagnostics, research, and therapeutics. The company tries to deliver transformational solutions that meet the requirement of research and developers throughout the life sciences with the utilization of its proprietary Optimer technology. The business of the company includes; aptamer diagnostics for in-house and collaborative optimizer-based diagnostic development, aptamer solutions for custom optimal development, and aptamer therapeutics for the development of optimal-based therapeutics. In June 2021, the company entered into a strategic collaboration agreement in order to develop Optimer-drug conjugates for targeted drug delivery combining the technology of Aptamer Group Optimer with the technology of PinotBio using the chemotherapeutic FL-118 compound with a specific linker.
SomaLogic Operating Co. Inc. operates as a protein biomarker discovery and clinical diagnostics company. The company is a leading provider of custom Optimer selection and development services. The company provides equipment for detecting cancer development, the beginning of metabolic diseases, the state of nutrition, and the future risk of stroke and heart attack. The company serves the healthcare industry in the United States. Optimer binders are next-generation aptamers offering high affinity, high stability, high specificity, and cost-effective production to enable innovations throughout the life sciences. In March 2022, the company announced the initiation of assaying samples using SomaScan Assay for the European Prospective Investigation into the Cancer and Nutrition study by analyzing 210 million protein measurements from 30,000 samples. This will assist researchers in predicting cancer by better understanding its nature, which may contribute to the growth of the market by addressing the rising demand.
Key Companies in the Aptamers market include
Aptamers Industry Developments
March 2022:Apatmer Science announced that a candidate material for ‘Corona-19 virus neutralizing aptamer’ has been chosen as a non-clinical support project of the Covid-19 treatments and vaccine new drug development project group.
March 2021:A pharmaceutical and biotechnology company, AstraZeneca, announced that they had extended their oligonucleotide drug delivery collaboration with Aptamer Group, a biotechnology company. This collaboration will help to research and identify new-targeting aptamers for delivering drug molecules to the target renal cells.
November 2017:Base Pair Biotechnologies, Inc. gained USD 3.2 million from investors like Eventi Capital Partners Inc. and Bio Tex Inc. This funding will be used for acquiring new lab instruments and other technologies to help them to expand its cellular and molecular analysis capabilities.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 2.3 Billion |
| Market Size 2023 | USD 2.74 Billion |
| Market Size 2032 | USD 11.42 Billion |
| Compound Annual Growth Rate (CAGR) | 19.50% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, The Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The US, German, Canada, France, UK, Italy, Spain, Japan, India, China, Australia, South Korea, and Brazil |
| Key Companies Profiled | SomaLogic Operating Co., Inc., Aptamer Group Inc, Aptagen LLC, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., Aptus Biotech SL, TriLink Biotechnologies, AstraZeneca, AM Biotechnologies, Aptadel Therapeutics, Ophthotech Corporation |
| Key Market Opportunities | An increasing number of products are under clinical investigation and academic research. |
| Key Market Dynamics | Increased research and development expenses and constant technological advances. |
Aptamers Market Highlights:
Frequently Asked Questions (FAQ) :
The Aptamers market size valued at USD 2.3 Billion in 2022.
The market is foreseen to raise at a CAGR of 19.50% throughout the forecast period, 2023-2032.
The North America had biggest share of the market
The key players in the market are SomaLogic Operating Co., Inc., Aptamer Group Inc, Aptagen LLC, Aptamer Sciences Inc., Base Pair Biotechnologies Inc., Aptus Biotech SL, TriLink Biotechnologies, AstraZeneca, AM Biotechnologies, Aptadel Therapeutics, and Ophthotech Corporation.
The Nucleic Acid Aptamer category dominated the market in 2022.
Research & development had the largest share in the market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
